{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gounder MM"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["2479-2490"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9467680"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(22)"],"pubmed_abstract":["<h4>Purpose</h4>Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.<h4>Methods</h4>SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT026"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial."],"pmcid":["PMC9467680"],"funding_grant_id":["P30 CA008748","UL1 TR001863"],"pubmed_authors":["Jones RL","Dickson MA","Stacchiotti S","Penel N","Kauffman MG","Hatcher H","Beveridge RD","Ben-Shahar O","Hartner L","Forscher C","Burgess M","Badalamenti G","Mulcahy MF","Elias A","Gonzalez AE","Chmielowski B","Van Tine BA","Meyer C","Napolitano A","Loggers ET","Shah JJ","Kasper B","Vincenzi B","Schwartz GK","Duffaud F","Michel D","Li L","Nicholas G","Ryan C","Yakobson A","Attia S","Blay JY","Gounder MM","Eriksson M","Somaiah N","Razak AA","Piperno-Neumann S","Chevreau C","Liu J","Ganjoo KN","Herraez AC","Mazzeo F","Lapeire L","Alcindor T","Chen JL","Groschel S","Zick A","Lee A","Le Cesne A","Riedel RF","Martin-Broto J","Garcia Del Muro X","Gotze K","Chang H","Chawla S","Philip T","Wagner AJ","von Mehren M","Davis EJ","Reichardt P","Grignani G","Okuno S","Landesman Y","Italiano A","Shacham S","Valverde Morales CM","Schuetze SM","Meng C","Van Domelen DR","Deshpande H","Walker CJ"],"additional_accession":[]},"is_claimable":false,"name":"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.","description":"<h4>Purpose</h4>Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.<h4>Methods</h4>SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT026","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T23:36:28.837Z","creation":"2025-02-19T00:44:12.144Z"},"accession":"S-EPMC9467680","cross_references":{"pubmed":["35394800"],"doi":["10.1200/JCO.21.01829"]}}